India Cements Capital Regulatory Approval

Open Offer

India Cements Capital Open Offer: ₹6.77 Cr

Acquirers have made an open offer to purchase up to 56.44 lakh equity shares of India Cements Capital Ltd at a price of ₹12 per share.

Value

₹6.77 Cr

Other Announcement

India Cements Capital Other Announcement

India Cements Capital Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under Regulation 31(1)(b) of the SEBI LODR Regulations.

Annual General Meeting

India Cements Capital Annual General Meeting

India Cements Capital filed the 40th AGM proceedings summary from 15 September 2026. The chairman recapped FY2026 results and the open offer to buy the company's shares.

Annual General Meeting

India Cements Capital Annual General Meeting

India Cements Capital Limited will hold its 40th Annual General Meeting on September 15, 2026. The company also filed its Annual Report for the fiscal year 2026.

Open Offer

India Cements Capital Open Offer: ₹6.77 Cr

The acquirers filed a Draft Letter of Offer to purchase up to 56,43,612 shares of India Cements Capital Ltd. The open offer is valued at ₹6.77 Crore.

Value

₹6.77 Cr

Management Change

India Cements Capital Management Change

India Cements Capital Limited reappointed Mr. K. Suresh as Manager/CEO and Mr. V. Manickam as Non-Executive Director. The Board also convened the upcoming Annual General Meeting.

Execution

01.10.2026 to 30.09.2027

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.